PD‐1 inhibitors interrupt the binding of PD‐L1 and PD‐L2, whereas PD‐L1 inhibitors preserve PD‐1/PD‐L2 signaling, which has potential clinical implications given the prognostic role of PD‐L2 in NSCLC [16, 23]. This evidence concerns the gene PDCD1LG2 and non-small cell lung carcinoma.